Gregory A. Vidal

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 560 citations · Full text

Medicine, Oncology, Pharmacology +17

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

Christopher C. Williams, June G. Allison, Gregory A. Vidal et al. · The Journal of Cell Biology · 2004 · 258 citations · Full text

Life Sciences, Biochemistry, Cell Biology +16

The ERBB4/HER4 Intracellular Domain 4ICD Is a BH3-Only Protein Promoting Apoptosis of Breast Cancer Cells

Anjali Naresh, Weiwen Long, Gregory A. Vidal et al. · Cancer Research · 2006 · 207 citations · Full text

Life Sciences, Biochemistry, Oncology +17

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · Journal of Clinical Oncology · 2018 · 141 citations

Medicine, Oncology, Pharmacology +13